Synthesis and Study of the Effect New Pyrazoles and Oxadiazole Linked to the 1,4-Dihydropyridine Ring on Breast Cancer

The Hantzsch reaction created a new series comprising 1,4-dihydropyridine pyrazoles and oxa diazoles (DHP) by initially synthesizing DHP esters, then its carbohydrates, and subsequent treatment with hydrazine. Pyrazole derivatives (Am1 and Am2) were obtained via the reaction of hydrazines with acetylacetone or ethyl acetoacetate, whereas the oxadiazole derivative (Am3) was prepared via reaction with carbon disulfide in an alkaline medium. The prepared compounds were identified using spectroscopic techniques (FTIR, 1H and 13C NMR, and mass spectrometry). The anti-breast cancer activity of new compounds was evaluated. This cytotoxicity activity afforded that compound (AS) was the strongest in this group together with an IC50 = 100.24µg mL-1, whereas compound (AT) demonstrated the lowest potency, with an IC50 value of 300 µg mL-1. The Hantzsch reaction was used in the synthesis of a new 1,4-dihydropyridine that has pyrazole and oxadiazole moieties. The activity of in vitro cytotoxicity (MTT cell viability assay) was determined. In vitro MCF7 cells were used in the evaluation of the cytotoxicity activity (MTT cell viability assay) of new compounds. This cytotoxicity activity meant that compound (AS) was the strongest in this group, with an IC50 of 100.24 µg mL-1, while compound (AT) had the least potency, with an IC50 value of 300 µg mL-1. Based on our findings, we can infer that 1,4-dihydropyridine derivatives (DHPs) are noteworthy heterocyclic compounds with pharmacological potential.  This cytotoxicity activity meant that compound (AS) was the strongest in this group, with an IC50 of 100.24 µg mL-1, while compound (AT) had the least potency, with an IC50 value of 300 µg mL-1.